Advances in the Study of Lynch Syndrome Associated Endometrial Cancer

LIU Xiao; LI Yulan; MA Xing; XU Feixue

doi:10.12290/xhyxzz.2022-0189

Volume 14 Issue 1

Jan. 2023

Turn off MathJax

Article Contents

Abstract

References

Medical Journal of Peking Union Medical College Hospital > 2023 > 14(1): 190-195. > DOI: 10.12290/xhyxzz.2022-0189

LIU Xiao, LI Yulan, MA Xing, XU Feixue. Advances in the Study of Lynch Syndrome Associated Endometrial Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 190-195. DOI: 10.12290/xhyxzz.2022-0189

Citation:

PDF (1428 KB)

Advances in the Study of Lynch Syndrome Associated Endometrial Cancer

1.
The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China
2.
Department of Obstetrics and Gynecology, Gansu Provincial Key Laboratory of Gynecological Oncology, First Hospital of Lanzhou University, Lanzhou 730000, China

Funds:

Science and Technology Project of Gansu Province 21JR7RA378

More Information

Corresponding author:
XU Feixue, E-mail: xfx.sxq@163.com
Received Date: April 06, 2022
Accepted Date: April 14, 2022
Available Online: May 30, 2022
Issue Publish Date: January 29, 2023

Graphical Abstract

Abstract

Abstract

Lynch syndrome (LS), an autosomal dominant genetic disorder caused by mismatch repair gene defects, is characterized by the susceptibility to multi-system malignancies. LS associated endometrial cancer (LS-EC) is the most common extraintestinal sentinel cancer of LS. In the era of precision medicine, early screening of LS-EC is of great significance to preventing the occurrence of other LS related malignant tumors. This paper reviews the research progress on screening methods and prevention of LS-EC, in order to provide reference for precise diagnosis and prevention of LS-related tumors.
- Lynch syndrome,
- endometrial cancer,
- sentinel cancer,
- mismatch repair gene,
- screening

FullText(HTML)

References (30)

References

[1]	Dörk T, Hillemanns P, Tempfer C, et al. Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management[J]. Cancers (Basel), 2020, 12: 2407. DOI: 10.3390/cancers12092407
[2]	Zhao S, Chen L, Zang Y, et al. Endometrial cancer in Lynch syndrome[J]. Int J Cancer, 2022, 150: 7-17. DOI: 10.1002/ijc.33763
[3]	Pastor DM, Schlom J. Immunology of Lynch Syndrome[J]. Curr Oncol Rep, 2021, 23: 96. DOI: 10.1007/s11912-021-01085-z
[4]	Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome[J]. Histopathology, 2010, 56: 167-179. DOI: 10.1111/j.1365-2559.2009.03392.x
[5]	Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study[J]. Lancet Oncol, 2011, 12: 49-55. DOI: 10.1016/S1470-2045(10)70265-5
[6]	Morak M, Ibisler A, Keller G, et al. Comprehensive analysis of the MLH1 promoter region in 480 patients with colorectal cancer and 1150 controls reveals new variants including one with a heritable constitutional MLH1 epimutation[J]. J Med Genet, 2018, 55: 240-248. DOI: 10.1136/jmedgenet-2017-104744
[7]	Dominguez-Valentin M, Sampson JR, Seppälä TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database[J]. Genet Med, 2020, 22: 15-25. DOI: 10.1038/s41436-019-0596-9
[8]	Ryan NAJ, Morris J, Green K, et al. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies[J]. JAMA Oncol, 2017, 3: 1702-1706. DOI: 10.1001/jamaoncol.2017.0619
[9]	Staff S, Aaltonen M, Huhtala H, et al. Endometrial cancer risk factors among Lynch syndrome women: a retrospective cohort study[J]. Br J Cancer, 2016, 115: 375-381. DOI: 10.1038/bjc.2016.193
[10]	Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma[J]. Cancer, 2006, 106: 87-94. DOI: 10.1002/cncr.21560
[11]	Rossi L, Le Frere-Belda MA, Laurent-Puig P, et al. Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome: A French Multicenter Study[J]. Int J Gynecol Cancer, 2017, 27: 953-960. DOI: 10.1097/IGC.0000000000000985
[12]	Ramchander NC, Ryan NAJ, Walker TDJ, et al. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer[J]. Front Immunol, 2020, 10: 3023. DOI: 10.3389/fimmu.2019.03023
[13]	Bogani G, Tibiletti MG, Ricci MT, et al. Lynch syndrome-related non-endometrioid endometrial cancer: analysis of outcomes[J]. Int J Gynecol Cancer, 2020, 30: 56-61. DOI: 10.1136/ijgc-2019-000824
[14]	Carr C, Son J, Yao M, et al. Clinicopathologic characteri-stics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening[J]. Gynecol Oncol, 2020, 159: 712-720. DOI: 10.1016/j.ygyno.2020.09.039
[15]	杨子慧, 刘新宇, 杨曦, 等. 林奇综合征患者子宫内膜癌及卵巢癌的筛查与预防[J]. 国际妇产科学杂志, 2021, 48: 453-456. Yang ZH, Liu XY, Yang X, et al. Screening and prevention of endometrial carcinoma and ovarian cancer in patients with Lynch syndrome[J]. Guoji Fuchanke Zazhi, 2021, 48: 453-456. DOI: 10.12280/gjfckx.20201174
[16]	Raevaara TE, Korhonen MK, Lohi H, et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1[J]. Gastroenterology, 2005, 129: 537-549.
[17]	Leclerc J, Vermaut C, Buisine MP. Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors[J]. Cancers (Basel), 2021, 13: 467. DOI: 10.3390/cancers13030467
[18]	Dietmaier W, Wallinger S, Bocker T, et al. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression[J]. Cancer Res, 1997, 57: 4749-4756.
[19]	Houlleberghs H, Dekker M, Lusseveld J, et al. Three-step site-directed mutagenesis screen identifies pathogenic MLH1 variants associated with Lynch syndrome[J]. J Med Genet, 2020, 57: 308-315. DOI: 10.1136/jmedgenet-2019-106520
[20]	Gallon R, Gawthorpe P, Phelps RL, et al. How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies[J]. Cancers (Basel), 2021, 13: 406. DOI: 10.3390/cancers13030406
[21]	Lu KH, Broaddus RR. Endometrial Cancer[J]. N Engl J Med, 2020, 383: 2053-2064. DOI: 10.1056/NEJMra1514010
[22]	Van den Heerik ASVM, Horeweg N, De Boer SM, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy[J]. Int J Gynecol Cancer, 2021, 31: 594-604. DOI: 10.1136/ijgc-2020-001822
[23]	Gompel A. Progesterone and endometrial cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2020, 69: 95-107. DOI: 10.1016/j.bpobgyn.2020.05.003
[24]	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency[J]. N Engl J Med, 2015, 372: 2509-2520. DOI: 10.1056/NEJMoa1500596
[25]	Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsa-tellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase Ⅱ KEYNOTE-158 Study[J]. J Clin Oncol, 2020, 38: 1-10.
[26]	Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial[J]. Lancet, 2020, 395: 1855-1863. DOI: 10.1016/S0140-6736(20)30366-4
[27]	Seppälä TT, Dominguez-Valentin M, Crosbie EJ, et al. Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospec-tive Lynch Syndrome Database report[J]. Eur J Cancer, 2021, 148: 124-133. DOI: 10.1016/j.ejca.2021.02.022
[28]	Crosbie EJ, Ryan NAJ, Arends MJ, et al. Manchester International Consensus Group, Evans DG. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome[J]. Genet Med, 2019, 21: 2390-2400. DOI: 10.1038/s41436-019-0489-y
[29]	Roudko V, Cimen Bozkus C, Greenbaum B, et al. Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines[J]. Front Immunol, 2021, 12: 757804. DOI: 10.3389/fimmu.2021.757804
[30]	Bayó C, Jung G, Español-Rego M, et al. Vaccines for Non-Viral Cancer Prevention[J]. Int J Mol Sci, 2021, 22: 10900. DOI: 10.3390/ijms222010900

Cited By

Cited by

Periodical cited type(2)

1.	张二新，魏继红，张鑫，阮晓红. 分子分型在指导子宫内膜癌患者保留生育功能治疗中的应用. 中国计划生育和妇产科. 2024(03): 33-35+39 .
2.	卢会娟，刘剑，邱毓琪，陈勇，王夙斐，鲁锦志，李爽，易村犍. Lynch综合征相关的子宫内膜癌1例并文献分析. 现代肿瘤医学. 2023(20): 3831-3835 .

Other cited types(1)

Get Citation

PDF

XML

Article Metrics

Article views (409) PDF downloads (68) Cited by(3)

Address：	Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
Tel：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
Copyright of website：	Editorial Office of Medical Journal of Peking Union Medical College Hospital

Advances in the Study of Lynch Syndrome Associated Endometrial Cancer

Abstract

References

Cited by

Periodical cited type(2)

Other cited types(1)

Catalog

Article Metrics

Related

Export File

Citation

Format

Content